At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the first interim analysis of the phase III prospective Lyma study of rituximab maintenance versus wait and watch after four courses of rituximab, dexamethasone, cytarabine and cisplatin (R-DHAP) followed by autologous stem cell transplantation (ASCT) in previously untreated young patients (under 66 years old) with mantle cell lymphoma.